DrugPatentWatch Database Preview
Oxaprozin - Generic Drug Details
What are the generic sources for oxaprozin and what is the scope of patent protection?
Oxaprozin
is the generic ingredient in three branded drugs marketed by Gd Searle, Actavis Elizabeth, Amneal Pharms Co, Apotex Inc, Beximco Pharms Usa, Dr Reddys Labs Ltd, Ivax Sub Teva Pharms, Mylan, Mylan Pharms Inc, Sandoz, Sun Pharm Inds Inc, Teva, and Watson Labs, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.There are thirteen drug master file entries for oxaprozin. Fourteen suppliers are listed for this compound.
Summary for oxaprozin
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 13 |
| NDAs: | 15 |
| Drug Master File Entries: | 13 |
| Suppliers / Packagers: | 14 |
| Bulk Api Vendors: | 86 |
| Clinical Trials: | 4 |
| Patent Applications: | 6,912 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for oxaprozin |
| Drug Sales Revenues: | Drug sales revenues for oxaprozin |
| DailyMed Link: | oxaprozin at DailyMed |
Recent Clinical Trials for oxaprozin
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fuji Yakuhin Co., Ltd. | Phase 1 |
| Mochida Pharmaceutical Company, Ltd. | Phase 1 |
| Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
Pharmacology for oxaprozin
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Synonyms for oxaprozin
| .beta.-(4,5-Diphenyloxazol-2-yl)propionic acid |
| 2-Oxazolepropanoic acid, 4,5-diphenyl- |
| 2-Oxazolepropanoic acid,5-diphenyl- |
| 2-OXAZOLEPROPIONIC ACID, 4,5-DIPHENYL- |
| 2-Oxazolepropionic acid,5-diphenyl- |
| 21256-18-8 |
| 256O188 |
| 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid |
| 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid |
| 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid # |
| 3-(4,5-Diphenyl-2-oxazolyl)propanoic acid |
| 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid |
| 3-(4,5-Diphenyl-2-oxazolyl)propionic acid |
| 3-(4,5-Diphenyl-oxazol-2-yl)-propionic acid |
| 3-(4,5-Diphenyloxazol-2-yl)propanoic acid |
| 3-(diphenyl-1,3-oxazol-2-yl)propanoic acid |
| 4, 5-Diphenyl-2-oxazolepropionic acid |
| 4,5-Diphenyl-2-oxazolepropanoic acid |
| 4,5-Diphenyl-2-oxazolepropionic acid |
| 4,5-diphenyloxazole-2-propanoic acid |
| 4.5-Diphenyl-2-oxazolepropanoic acid|||Daypro |
| A815225 |
| AB0011812 |
| AB00514024 |
| AB00514024_08 |
| AB00514024_09 |
| AC-26512 |
| AC1L1IK7 |
| AC1Q759J |
| AC1Q759K |
| Actirin |
| AJ-08102 |
| AKOS000206807 |
| Alvo |
| ANW-63377 |
| B1804 |
| BCP28431 |
| BDBM50002861 |
| beta-(4,5-Diphenyloxazol-2-yl)propionic acid |
| BIDD:GT0438 |
| BIDD:PXR0149 |
| BPBio1_001122 |
| BRD-K25394294-001-05-7 |
| BRD-K25394294-001-08-1 |
| BRN 1083168 |
| BSPBio_001020 |
| BSPBio_002696 |
| C07356 |
| C18H15NO3 |
| CAS-21256-18-8 |
| CCG-36508 |
| CHEBI:7822 |
| CHEMBL1071 |
| CPD000058286 |
| CS-7975 |
| CTK7J3117 |
| D00463 |
| Danoprox |
| Daypro |
| Daypro (TN) |
| Dayrun |
| DB00991 |
| Deflam |
| DSSTox_CID_25118 |
| DSSTox_GSID_45118 |
| DSSTox_RID_80684 |
| DTXSID1045118 |
| Durapro |
| Duraprost |
| EINECS 244-296-1 |
| EN300-25629 |
| EU-0100944 |
| FT-0638104 |
| GTPL7252 |
| HMS1571C22 |
| HMS1922P17 |
| HMS2051L15 |
| HMS2093O08 |
| HMS2098C22 |
| HMS3262N10 |
| HMS3393L15 |
| HMS3652H17 |
| HMS3715C22 |
| HMS566H22 |
| HSDB 7586 |
| HY-B0808 |
| I14-8703 |
| J-013955 |
| J10396 |
| K-6109 |
| KB-59357 |
| KBio3_001916 |
| KBioGR_001722 |
| KS-00000ULR |
| KS-5196 |
| Lopac-O-9637 |
| Lopac0_000944 |
| LP00944 |
| LS-100216 |
| Maybridge1_008800 |
| MCULE-7099031811 |
| MFCD00215977 |
| MHJ80W9LRB |
| MLS000759535 |
| MLS001424072 |
| MolPort-000-146-829 |
| NC00214 |
| NCGC00014711 |
| NCGC00014711-01 |
| NCGC00014711-02 |
| NCGC00014711-03 |
| NCGC00014711-04 |
| NCGC00014711-05 |
| NCGC00014711-06 |
| NCGC00014711-07 |
| NCGC00014711-08 |
| NCGC00014711-09 |
| NCGC00014711-10 |
| NCGC00014711-11 |
| NCGC00014711-14 |
| NCGC00014711-15 |
| NCGC00094249-01 |
| NCGC00094249-02 |
| NCGC00094249-03 |
| NCGC00094249-04 |
| NCGC00094249-05 |
| NCGC00094249-06 |
| NCGC00094249-07 |
| NCGC00261629-01 |
| NCI310839 |
| NCI60_002681 |
| NCIStruc1_000799 |
| NCIStruc2_000787 |
| NSC 310839 |
| NSC-310839 |
| NSC-758949 |
| NSC310839 |
| NSC758949 |
| O 9637 |
| O0377 |
| OFPXSFXSNFPTHF-UHFFFAOYSA-N |
| Oprea1_509470 |
| Oxapro |
| oxaprosin |
| Oxaprozi |
| Oxaprozin (JP17/USAN/INN) |
| Oxaprozin [USAN:BAN:INN:JAN] |
| Oxaprozin [USAN:USP:INN:BAN:JAN] |
| Oxaprozin, solid |
| Oxaprozin, United States Pharmacopeia (USP) Reference Standard |
| Oxaprozin,(S) |
| Oxaprozina |
| Oxaprozina [INN-Spanish] |
| Oxaprozine |
| Oxaprozine [INN-French] |
| Oxaprozinum |
| Oxaprozinum [INN-Latin] |
| Pharmakon1600-01505267 |
| Prestwick0_001060 |
| Prestwick1_001060 |
| Prestwick2_001060 |
| Prestwick3_001060 |
| s4230 |
| SAM001246770 |
| SBB053166 |
| SBI-0050918.P002 |
| SC-13926 |
| SCHEMBL3286 |
| SMR000058286 |
| SPBio_001652 |
| SPBio_002940 |
| SPECTRUM1505267 |
| Spectrum2_001696 |
| Spectrum3_001078 |
| Spectrum4_001231 |
| SR-01000076053 |
| SR-01000076053-1 |
| SR-01000076053-3 |
| SR-01000076053-7 |
| SR-01000076053-9 |
| ST50949623 |
| SW197319-4 |
| TC-152122 |
| Tox21_110059 |
| Tox21_110059_1 |
| Tox21_500944 |
| UNII-MHJ80W9LRB |
| Voir |
| Walix |
| WY 21743 |
| WY-21,743 |
| WY-21743 |
| Xopane |
| Z217102860 |
| ZINC49643479 |
US Patents and Regulatory Information for oxaprozin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | OXAPROZIN | oxaprozin | TABLET;ORAL | 075845-001 | Jan 31, 2001 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Sandoz | OXAPROZIN | oxaprozin | TABLET;ORAL | 075850-001 | Apr 27, 2001 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Dr Reddys Labs Ltd | OXAPROZIN | oxaprozin | TABLET;ORAL | 075855-001 | Jan 31, 2001 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.